Please assess the completion status of the following clinical trial:

Trial Title: Effect of DPP4 Inhibition on Growth Hormone Secretion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 40 years inclusive~* BMI ≤ 25 kg/m2~* For female subjects:~Status-post surgical sterilization, or If of child-bearing potential, utilization of a barrier method of birth control following negative serum pregnancy test at screening visit and on every study day~Exclusion Criteria:~* Smoking~* Type 1 or Type 2 Diabetes Mellitus, as defined by a fasting glucose of 126 mg/dL or greater at the time of screening visit or the use of anti-diabetic medication~* Hypertension, as defined by an untreated seated systolic blood pressure (SBP) greater than 140 mmHg and/or an untreated diastolic blood pressure (DBP) greater than 90 mmHg at the time of screening visit or the use of anti-hypertensive medication~* History of reported or recorded hypoglycemia (plasma glucose \< 70 mg/dL)~* Pregnancy and/or Breast-Feeding~* Use of any medication other than multivitamin, including use of transdermal as well as oral hormone replacement therapy or use of oral contraceptive therapy~* Anemia defined as hematocrit \<35% at screening visit~* Cardiovascular or cerebrovascular disease, including history of myocardial infarction, history of congestive heart failure, history of stroke~* Pulmonary Hypertension~* Abnormal thyroid hormone levels (TSH) at the time of screening visit~* Abnormal serum insulin like growth factor-1 (IGF-1) at the time of screening visit~* Impaired renal function, defined as estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m\^2~* Impaired hepatic function (alanine or aspartate transaminase \> 2 X upper limit of normal range)~* Treatment with an investigational drug in the 1 month preceding the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Group A (14 healthy subjects) (Type: OTHER): In Aim 1: Healthy Lean adults are randomized in a double-blinded cross over fashion to sitagliptin versus placebo.~In Aim 2: Healthy Lean adults receive sitagliptin and are randomized in a double-blinded cross over fashion to pre-treatment with either LNMMA (L-N-Monomethyl-arginine) versus placebo.
- Group B (14 healthy subjects) (Type: OTHER): In Aim 1: Healthy Lean adults are randomized in a double-blinded cross over fashion to sitagliptin versus placebo.~In Aim 2: Healthy Lean adults receive sitagliptin and are randomized in a double-blinded cross over fashion to pre-treatment with either pegvisomant versus placebo.
- Group C (14 healthy subjects) (Type: OTHER): In Aim 1: Healthy Lean adults are randomized in a double-blinded cross over fashion to sitagliptin versus placebo.~In Aim 2: Healthy Lean adults receive sitagliptin and are randomized in a double-blinded cross over fashion to pre-treatment with either Exendin 9-39 versus placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).